By Fineline Cube 
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced plans to invest USD 23 billion over the next five years to build and expand ten facilities across the United States, including seven brand-new sites. This strategic initiative ensures domestic production of all key Novartis medicines for U.S. patients and brings the company’s total U.S. investment to USD 50 billion through 2029.
Job Creation and Economic Impact
The commitment is expected to create 1,000 new jobs at Novartis, alongside an additional 4,000 job opportunities across the U.S. supply chain. The expanded production capacity will cover active pharmaceutical ingredients (API), biologics drug substance, secondary production, and packaging, reinforcing Novartis’ role as a key contributor to the U.S. pharmaceutical sector.
Facility Details and Innovation Hubs
The investment will fund the establishment of one biomedical research innovation hub in San Diego, CA, marking Novartis’ second global R&D hub in the U.S. Four new manufacturing facilities will be built in states yet to be determined, including three dedicated to biologics drug substances, drug products, device assembly, and packaging, and one focused on chemical drug substances, oral solids dosage forms, and packaging. Additionally, two new radioligand therapy (RLT) manufacturing facilities will be established in Florida and Texas, alongside expansions of three existing RLT facilities in Indianapolis, IN, Millburn, NJ, and Carlsbad, CA.-Fineline Info & Tech